RECELL Growth Opportunity exists to expand adoption of the RECELL System in burn centers and trauma networks, leveraging rising Q2 revenue drivers and leadership focus to upsell to hospitals expanding acute wound care capabilities.

Product Line Expansion Cross-sell potential for Cohealyx and PermeaDerm alongside RECELL, targeting facilities seeking integrated dermal matrix and biosynthetic wound care solutions to streamline procurement and improve outcomes.

International Expansion Recent UK clinical activity signals readiness for broader international rollout; focus on partnerships with burn units and distributors in Europe and other high-need markets to accelerate geographic growth.

Clinical Evidence Leverage interim and real-world data showing faster readiness for skin grafting to support value-based selling and competitive differentiation against other wound care products.

Strategic Partnerships Engage with key burn centers, hospital systems, and Wound Care networks for joint clinical studies, training programs, and net-new collaborations to accelerate sales momentum and deployment of AVITA’s platform.